ChartMill · Oct 2, 2026
Kiniksa Pharmaceuticals (NASDAQ:KNSA): Affordable Growth Backed by Accelerating Earnings
KNSA: commercial-stage biopharma with strong revenue growth, peer-relative value, solid health, and ARCALYST-led pipeline.
KN
NASDAQ · KNSA
Kiniksa Pharmaceuticals, Ltd.
Healthcare · Biotechnology
$77.09
Up+$0.87 (+1.13%)
Updated Oct 7, 2026, 10:32 PM
SID Score
5.8/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 3B
- P/E ratio
- 83.96
- Dividend yield
- 0.00%
- 52-week range
- $35.20 – $82.94
- Volume
- 378.74K
- Avg. volume
- 427.35K
Price performance · KNSA
KNSA price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
KNSA closed at $77.09 after 21 trading sessions, up 0.00% for the selected period.
- Last close
- $77.09
- Period change
- +0.00%
- Period low
- $74.61
- Period high
- $79.33
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $76.00 | $77.32 | $73.84 | $77.09 | 378.74K |
| Oct 5, 2026 | $75.97 | $76.79 | $75.285 | $76.31 | 391.51K |
| Oct 2, 2026 | $75.58 | $76.22 | $74.5601 | $75.79 | 376.31K |
| Oct 1, 2026 | $73.87 | $76.11 | $73.14 | $75.22 | 878.56K |
| Sep 30, 2026 | $76.55 | $76.55 | $73.76 | $74.61 | 650.61K |
| Sep 29, 2026 | $75.32 | $76.52 | $74.33 | $75.73 | 620.7K |
| Sep 28, 2026 | $75.00 | $76.42 | $74.02 | $76.10 | 734.14K |
| Sep 25, 2026 | $75.40 | $76.00 | $74.5343 | $75.08 | 478.99K |
| Sep 24, 2026 | $76.02 | $76.949 | $74.46 | $75.34 | 433.36K |
| Sep 23, 2026 | $77.99 | $78.23 | $74.88 | $76.08 | 408.46K |
| Sep 22, 2026 | $78.09 | $79.54 | $77.371 | $78.00 | 404K |
| Sep 21, 2026 | $77.12 | $78.73 | $75.90 | $78.13 | 482.85K |
| Sep 18, 2026 | $78.95 | $79.61 | $76.99 | $77.24 | 1.06M |
| Sep 17, 2026 | $78.66 | $79.76 | $78.29 | $79.33 | 722.01K |
| Sep 16, 2026 | $75.06 | $77.64 | $74.91 | $77.62 | 553.9K |
| Sep 15, 2026 | $76.46 | $76.63 | $74.47 | $75.15 | 488.92K |
| Sep 14, 2026 | $77.89 | $77.89 | $75.02 | $76.58 | 646.08K |
| Sep 11, 2026 | $77.70 | $78.59 | $76.14 | $76.27 | 576.56K |
| Sep 10, 2026 | $77.66 | $78.4203 | $75.9859 | $76.48 | 459.84K |
| Sep 9, 2026 | $78.72 | $80.22 | $77.33 | $78.52 | 588.38K |
| Sep 8, 2026 | $76.25 | $78.50 | $75.00 | $77.09 | 677.3K |
Latest KNSA news
The latest Smart Investors Daily articles mentioning KNSA.
Stock researchCompany · Overview
Company
Market Activity
Research & News
KNSA research
Overview
Company profile and research snapshot.
Company profile
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $51.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 30, 2026 | Goldman Sachs | Buy | — |
| Jul 29, 2026 | Citigroup | Buy | — |
| Jul 29, 2026 | Wedbush | Outperform | — |
| Jul 29, 2026 | Canaccord Genuity | Buy | — |
| Jul 29, 2026 | JP Morgan | Overweight | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Oct 2, 2026
Kiniksa Pharmaceuticals Has Strong Growth And Little Room For Disappointment
Kiniksa Pharmaceuticals has a high share price and insufficient margin of safety despite strong ARCALYST commercial execution. Learn why KNSA stock is a hold.
ChartMill · Sep 28, 2026
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Pairs High Growth Momentum With a Breakout Setup
Kiniksa Pharmaceuticals (KNSA) stock shows high growth momentum, strong technicals, and a breakout setup. See key ratings, support, and risks.
Yahoo · Sep 23, 2026
Kiniksa Pharmaceuticals International (KNSA) On The ARCALYST Story And Whether Shares Look Fully Valued
Kiniksa Pharmaceuticals International (KNSA) has drawn fresh attention after recent share performance data highlighted sharp swings, with the stock down about 4% over the past month but up roughly 34% in the past 3 months. Short term momentum for Kiniksa Pharmaceuticals International has cooled a little, with the share price down over the past month. However, the 90 day share price return of 33.73% and year to date gain of 81.12% point to a strong upswing overall. Compare Kiniksa...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
